EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Assessment of physiological changes and levels of KIM-1 and MDA Biomarkers resulting from TDM on Vancomycin-Induced Subclinical Nephrotoxicity for Pediatrics in Al-Najaf city: Case-control study

Ahmed Hasan Kadhim, Nagham Yahya Ghafil

Wiadomości Lekarskie · 2026-09-30 · (9) · 2173-2179

DOI: 10.36740/wlek/231649 ↗
AbstractBibliografische Angaben

Abstract

Aim Background: Among pediatric populations, Vancomycin retains its standing as a fundamental agent against severe Gram-positive infections. Nevertheless, its pharmacokinetic profile fluctuates according to developmental stage, and such inconsistency renders serum levels difficult to forecast. This lack of predictability, in turn, heightens the likelihood of therapeutic failure. Objective: The present investigation set out to evaluate the physiological alterations together with the concentrations of the KIM-1 and MDA biomarkers as they relate to TDM-guided Vancomycin treatment. Material and methods Methodology: A prospective case-control study was undertaken at Al-Zahraa Teaching Hospital, Al-Najaf, Iraq, recruiting 140 pediatric patients receiving intravenous Vancomycin. Through random allocation, participants entered either a control arm administered conventional empirical doses n=70 or a case arm in which dosing was refined by means of pharmacist-led TDM guidance (n=70). Results Results: The institution of pharmacist-led therapeutic drug monitoring (TDM) markedly enhanced attainment of Vancomycin targets and promoted clinical recovery. Within the optimized-therapy group, KIM-1 concentrations declined substantially—signaling diminished renal tubular injury—whereas in those maintained on empirical therapy, these concentrations climbed. TDM-directed dose modifications further yielded a pronounced fall in MDA levels, denoting attenuated oxidative stress. Conclusions Conclusion: Pharmacist-led therapeutic drug monitoring bolsters both the safety and the efficacy of Vancomycin treatment in the pediatric setting. Calibrating the dose on the strength of TDM translated into superior clinical outcomes while restraining subclinical nephrotoxicity and oxidative stress, as evidenced by the pronounced decline in KIM-1 and MDA concentrations.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →